A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia.

Exclusion Criteria

• •Life expectancy \< 12 weeks
• •\< 3 weeks since the last anti-tumor therapy, including chemotherapy, biologic, experimental, hormonal or radiotherapy (with the exception of leuprolide or similar medications for prostate cancer)
• •Recent major surgical procedure or traumatic injury, or unhealed incisions or wounds
• •Active infection requiring IV antibiotics
• •Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis.
• •Primary CNS malignancy or untreated/active CNS metastases (progressing or requiring anticonvulsants or corticosteroids for symptomatic control)
• •History of other malignancy within 5 years prior to screening, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin cancer, Stage I uterine cancer, or other cancers with a similar outcome
• •Cardiovascular dysfunction, including ventricular dysrhythmias or risk factors for ventricular dysrhythmias
• •Pregnancy, or lactation
• •Any other diseases that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications